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ABSTRACT 
Kidney stones are a common condition causing significant morbidity and economic burden. The prevalence of Urolithiasis (Kidney stones) is 
increasing from past 20 years, worldwide 5-15% of the population affected by Urolithiasis. The most common type of kidney stone is calcium 
oxalate formed in the renal surfaces. The mechanism of stone formation is a complex process which results from several physicochemical 
events including supersaturation, nucleation, growth, aggregation, and retention of urinary stone constituents within tubular  cells. Obese 
people are known to have a higher risk of stone formation. Metabolic syndrome has resulted in an increasing rate of nephrolithiasis among 
women. The diagnosis and initial management of urolithiasis have undergone considerable evolution in recent years. This review article 
provides information about epidemiology, mechanism, diagnosis, and pathophysiology of kidney stone formation, and methods for the 
evaluation of stone risks for new and follow-up patients.  
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INTRODUCTION  
Urolithiasis is the presence of calculi in the kidney and/or in 
any part of the urinary tract, including the ureters and 
bladder and may develop in one or both of the kidneys. 
Nearly about 80% of these calculi are composed of calcium 
oxalate and phosphate.1 The lifetime risk of urinary stone 
disease is 12% in males and 6% in females.2 Urolithiasis is a 
complex process that is a consequence of an imbalance 
between promoters (calcium, sodium, oxalate, urate, cystine, 
low urine pH, low urine flow) and inhibitors (citrate, 
magnesium, pyrophosphate, Tamm Horsfall protein, urinary 
prothrombin fragments, glycosaminoglycan osteopontin, and 
high urine flow) in the kidneys.3 Calcium oxalate (CaOx) 
represents up to 80% of analyzed stone. Kidney stone 
formation is a complex process that results from a succession 
of several physicochemical events including supersaturation, 
nucleation, growth aggregation and retention within the 
renal tubules.3  
What are kidneys? 
The kidneys are two bean-shaped organs in the renal system. 
The kidneys extend from the level of the twelfth thoracic 
vertebra to the third lumbar vertebra. The left kidney is 
closer to the midline, longer and more slender than the right. 
They help the body pass waste as urine.2 They also help filter 
blood before sending it back to the heart. The renal hilum, an 
entrance to the space in the kidney called the renal sinus, is a 
cleft lying at the concave medial margin of the kidney and is 
where the structures serving the kidney enter and exit.2 
 
Fig.1: Urinary System Diagram  
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Fig.2: Structure of Kidney 
 
The kidneys perform many crucial functions, including: 
 Maintaining overall fluid balance 
 Regulating and filtering minerals from blood 
 Filtering waste materials from food, medications, and 
toxic substances 
 Creating hormones that help produce red blood cells, 
promote bone health, and regulate blood pressure 
Nephrons 
Nephrons are the most important part of each kidney. They 
take in blood, metabolize nutrients, and help pass out waste 
products from filtered blood. Each kidney has about 1 million 
nephrons. Each has its own internal set of structures. 
 
 
Fig.3: Nephron Anatomy 
 
Epidemiology of Urolithiasis 
The prevalence of urolithiasis is approximately 2 to 3 
percent in the general population, and the estimated lifetime 
risk of developing a kidney stone is about 12 percent for 
white males. Approximately 50 percent of patients with 
previous urinary calculi have a recurrence within 10 years.4 
Stone disease is two to three times more common in males 
than in females. It occurs more often in adults than in elderly 
persons, and more often in elderly persons than in children. 
Whites are affected more often than persons of Asian 
ethnicity, who are affected more often than blacks. In 
addition, urolithiasis occurs more frequently in hot, arid 
areas than in temperate regions. Decreased fluid intake and 
consequent urine concentration are among the most 
important factors influencing stone formation. Certain 
medications, such as triamterene (Dyrenium), indinavir 
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(Crixivan) and acetazolamide (Diamox), are also associated 
with urolithiasis. Dietary oxalate is another possible cause, 
but the role of dietary calcium is less clear, and calcium 
restriction is no longer universally recommended.5   
Presentation and Differential Diagnosis 
Urolithiasis should always be considered in the differential 
diagnosis of abdominal pain. The classic presentation of 
renal colic is excruciating unilateral flank or lower 
abdominal pain of sudden onset that is not related to any 
precipitating event and is not relieved by postural changes 
or nonnarcotic medications. With the exception of nausea 
and vomiting secondary to stimulation of the celiac plexus, 
gastrointestinal symptoms are usually absent. The pain of 
renal colic often begins as vague flank pain. Patients 
frequently dismiss this pain until it evolves into waves of 
severe pain. It is generally believed that a stone must at least 
partially obstruct the ureter to cause pain. The pain is 
commonly referred to the lower abdomen and to the 
ipsilateral groin. As the stone progresses down the ureter, 
the pain tends to migrate caudally and medially.4  
 
Table 1: Relationship of Stone Location to Symptoms4 
Stone Location Common Symptoms 
Kidney Vague flank pain, hematuria 
Proximal ureter Renal colic, flank pain, upper abdominal pain 
Middle section of ureter Renal colic, anterior abdominal pain, flank pain 
Distal ureter Renal colic, dysuria, urinary frequency, anterior abdominal pain, flank pain 
 
Kidney stone (Urolithiasis) formation 
When CaOx concentration is 4 times above the normal 
solubility a crystal starts to form. If the CaOx concentration 
is 7 to 11 times higher than normal solubility the nucleation 
begins. In low urine volume, the presence of high calcium, 
high oxalate the supersaturation (SS) of CaOx is increased. 
Citrate in the urine forms soluble complex with urinary Ca. If 
urine has low citrate concentration SS CaOx is promoted to 
form CaOx stone. If urine pH is > 6.5, proportion of divalent 
and trivalent ions are increased then SS CaP is favorable. The 
levels of urinary supersaturation of the different solutes 
determine the specific types of stones.6  
 
       
Fig. 4: Kidney stone formation 
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Fig. 5: Schematic representation of the various events of kidney stone formation.7 
 
TYPES OF KIDNEY STONES (UROLITHIASIS) 
Approximately 70-80% of kidney stones are composed of 
calcium oxalate and calcium phosphate. Of the rest, 10% are 
struvite, 10% of uric acid; and less than 1% are composed of 
cystine or are diagnosed as drug-related stones. Calcium and 
uric acid stones are more common in men; women have 
more struvite stones.6  
 
Table 2: Type of stones 
Type Frequency (%) Sex Crystals Radiography 
Calcium oxalate/ mix 75 M Envelope Round, radiodense, sharply outlined 
Calcium phosphate 
(brushite) 
5 F>M 
Amorphous: Alkaline 
urine 
Small, radiodense, sharply outlined 
Uric acid 5–15 M=F Diamond; Acid urine Round/ staghorn, radiolucent, filling defect 
Struvite (Mg 
ammonium 
phosphate) 
10–20 F 
Coffin lid; Infection/ urea 
splitter 
Staghorn, laminated radiodense 
Cystine 1 M=F Hexagon Staghorn, radiodense 
 
Urinary supersaturation 
(Promotors such as hyperoxaluria) 
Oxidative stress 
Cell injury and cell membrane rupture) 
Nucleation (Heterogeneous) 
Crystal growth 
Crystal aggregation 
Crystal-cell interaction 
Crystal retention/adhesion 
Stone formation 
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Fig.6: Chart showing % of Stone formation 
 
Kidney stones tend to recur approximately 50% people who 
form one stone form another within 10 years. The risk of 
recurrence ranges from 30-50% at 5 years in observational 
studies. The control groups in recent randomized controlled 
trials have a 2-5% annual recurrence rate after an incident 
calcium oxalate stone. Recurrence rates also depend on the 
stone type. When nuclei of uric acid form, they lower the 
metastable limit (e.g. susceptibility to perturbation) and 
favor further stone precipitation. Decreased supersaturation 
of the urine filtrate will decrease the risk of recurrence of 
kidney stone.8 
 Calcium stones 
Calcium oxalate stones are the most common type of kidney 
stone. Kidney stones are solid masses that form in the kidney 
when there are high levels of calcium, oxalate, cystine, or 
phosphate and too little liquid. Calcium stones are composed 
of calcium oxalate, either by itself or much more commonly 
in combination with calcium phosphate or calcium urate.9 
Hypercalciuria, low urine volume and hypocitraturia all 
predispose to the development of calcium stones. 
Hypercalciuria often occurs with diseases associated with 
hypercalcemia like hyperparathyroidism, malignancy, 
sarcoidosis and vitamin D excess.10 Alkaline urine is a risk 
factor for the development calcium phosphate stones. 
Another risk factor for calcium oxalate stone is 
hyperoxaluria, which occurs due to bowel disease (enteric 
hyperoxaluria) and genetic disorders of oxalate metabolism 
(primary hyperoxaluria).  
Dietary oxalate may be important in stone development; 
spinach, beets and rhubarb in particular, contain large 
amounts of oxalate and they may increase urinary oxalate 
excretion and predispose to the development of calcium 
oxalate stones. High dose vitamin C therapy can also lead to 
increased oxalate generation as vitamin C (ascorbic acid) is 
metabolized. Oxalate reabsorption in the colon is reduced by 
the formation of insoluble calcium oxalate. 11 
Diarrheal losses cause volume depletion and decreased urine 
volume. Bicarbonate loss in the stool can cause a metabolic 
acidosis which can in turn lead to a low urinary pH and 
hypocitraturia (due to enhanced proximal reabsorption) 
which will predispose to the development uric acid and 
calcium oxalate stone formation. 12 
 
Fig. 7: Calcium stones 
Symptom: 
A kidney stone may not cause symptoms until it moves 
around within your kidney or passes into your ureter the 
tube connecting the kidney and bladder. At that point, you 
may experience these signs and symptoms: 
 Severe pain in the side and back, below the ribs 
 Pain that radiates to the lower abdomen and groin 
 Pain that comes in waves and fluctuates in intensity 
 Pain on urination 
 Pink, red or brown urine 
 Cloudy or foul-smelling urine 
 Nausea and vomiting 
 Persistent need to urinate 
 Fever and chills if an infection is present 
 Urinating small amounts 
 Uric acid stones 
Pure uric acid calculi are radiolucent on plain radiographs 
but visible on ultrasonography or computerized tomography 
(CT). These stones tend to form in individuals with 
hyperuricosuria. Approximately 15-20% of patients with 
uric acid stones have a history of gout. A diet rich in animal 
protein, because of its high purine content, which produces 
uric acid in its catabolism, may increase the risk of uric acid 
stone formation. At a urinary pH of less than 5.5, uric acid is 
poorly soluble, but solubility increases at a pH greater than 
6.5.13  
75 % 
5% 
5-15% 
10-20% 
1% 
Stones 
Calcium oxalate/ mix
Calcium phosphate (brushite)
Uric acid
Struvite (Mg ammonium phosphate)
Cystine
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Fig.8: Uric acid stones 
 Cystine stones 
Cystine kidney stones are due to cystinuria, an inherited 
(genetic) disorder of the transport of an amino acid (a 
building block of protein) called cystine that results in an 
excess of cystine in the urine (cystinuria) and the formation 
of cystine stones. 
Cystinuria is the most common defect in the transport of an 
amino acid. Although cystine is not the only overly excreted 
amino acid in cystinuria, it is the least soluble of all naturally 
occurring amino acids. Cystine tends to precipitate out of 
urine and form stones (calculi) in the urinary tract. 
Small stones are passed in the urine. However, big stones 
remain in the kidney (nephrolithiasis) impairing the outflow 
of urine while medium-size stones make their way from the 
kidney into the ureter and lodge there further blocking the 
flow of urine (urinary obstruction). 
 
Fig.9: Cystine stones 
Symptoms:  
Cystinuria only causes symptoms if you have a stone.  Kidney 
stones can be as small as a grain of sand.  Others can become 
as large as a pebble or even a golf ball.  Symptoms may 
include: 
 Pain while urinating 
 Blood in the urine 
 Sharp pain in the side or the back (almost always 
on one side) 
 Pain near the groin, pelvis, or abdomen 
 Nausea and vomiting 
 Struvite stones 
Struvite stones are a type of hard mineral deposit that can 
form in your kidneys. Stones form when minerals like 
calcium and phosphate crystallize inside your kidneys and 
stick together. Struvite is a mineral that’s produced by 
bacteria in your urinary tract. 
About 10 to 15 percent of all kidney stones are made from 
struvite. This type of stone is more common in women than 
in men. Struvite stones can grow very quickly. Eventually, 
they can block your kidney, ureter, or bladder and damage 
your kidney. 
 
Fig.10: Struvite stones 
Symptom: 
Symptoms of struvite stones are similar to those of other 
types of stones, and can include: 
 Pain in your side and back 
 Fever 
 Frequent need to urinate 
 Pain when you urinate 
 Blood in your urine 
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Fig. 11: Mechanism of stone formation14 
 
Risk factors for kidney stones 15 
Factors that increase your risk of developing kidney stones 
include: 
 Family or personal history. 
If someone in your family has kidney stones, you're more 
likely to develop stones, too. And if you've already had one 
or more kidney stones, you're at increased risk of developing 
another. 
 Dehydration.  
Not drinking enough water each day can increase your risk 
of kidney stones. People who live in warm climates and 
those who sweat a lot may be at higher risk than others. 
 Certain diets.  
Eating a diet that's high in protein, sodium (salt) and sugar 
may increase your risk of some types of kidney stones. This 
is especially true with a high-sodium diet. Too much salt in 
your diet increases the amount of calcium your kidneys must 
filter and significantly increases your risk of kidney stones. 
 Being obese.  
High body mass index (BMI), large waist size and weight 
gain have been linked to an increased risk of kidney stones. 
 Digestive diseases and surgery.  
Gastric bypass surgery, inflammatory bowel disease or 
chronic diarrhea can cause changes in the digestive process 
that affect your absorption of calcium and water, increasing 
the levels of stone-forming substances in your urine. 
 Other medical conditions.  
Diseases and conditions that may increase your risk of 
kidney stones include renal tubular acidosis, cystinuria, 
hyperparathyroidism, certain medications and some urinary 
tract infections. 
 
Table 3: Stones classified according to their aetiology 
Noninfection Stones Infection stones Genetic stones Drug stones 
Calcium oxalates Magnesium ammonium 
phosphate (Struvite) 
Cystine Indinavir      
Calcium phosphates Apatite Xanthine 
Uric acid Ammonium urate 2,8-dihydroxyadenine 
 
Clinical presentation 
Pain is produced as a result of stone obstruction usually at 
uretro-pelvic junction, pelvic brim and vesico-ureteric 
junction. Urolithiasis may exist asymptomatically, but it is 
often presented by excruciating pain that originates from the 
flank and radiates to the genitals. Stone obstruction also 
produces lower abdominal cramps, dysuria, urinary urgency 
and strangury and also promotes the elevation of intrarenal 
pressure that induces prostaglandin synthesis, which again 
causes ureteric smooth-muscle spasm. Renal colic is 
generally associated with nausea and vomiting. Haematuria 
Age, Profession, Nutrition, Climate, Inheritance, Sex, Mentality,     Constitutions, 
Race 
Abnormal renal morphology, Disturbed urine flow, Urinary tract  infection, 
Metabolic abnormalities, Genetic factors 
Increased excretion stone forming constituents, Decreased excretion of inhibitors 
of crystallizations 
Physico-chemical change in the state of supersaturation 
Abnormal crystalluria, Crystal’s aggregations, Crystal’s growth 
Formation of stone 
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and infection are also common symptoms associated with 
renal stone disease. Urinary tract infection (UTI) may be a 
result of stone obstruction or may be the cause of 
magnesium ammonium phosphate (struvite) stones also 
called the infection stones. Fever, chills and pus formation 
are usually associated with infection stones.16, 17, 18  
Diagnosis of Urolithiasis  
Initial evaluation includes obtaining a non-contrast helical 
CT, which can accurately visualize the size and location of the 
stones. A kidney, ureter and bladder (KUB) film, although it 
is insensitive to uric acid stones since they are radiolucent 
and therefore are not visualized. However, it can visualize 
calcium containing, struvite and cystine stones in the kidney 
or ureter. Complete ureteral obstruction and upper urinary 
tract infection (UTI) are indications for stone removal by 
extracorporeal shock wave lithotripsy (ESWL) or surgery.6   
Based on clinical symptoms of the location and severity of 
the pain diagnosis is done. Imaging like x-ray, computed 
tomography, ultrasound is used to confirm the diagnosis and 
a number of other tests can be undertaken to help establish 
both the possible cause and consequences of the stone.19  
Other diagnostic methods 
Other investigations typically carried out include: 
 Microscopic study of urine, which may show 
proteins, red blood cells, bacteria, cellular casts and crystals. 
 Culture of a urine sample to exclude urine infection 
(either as a differential cause of the patient's pain, or 
secondary to the presence of a stone). 
Laboratory evaluation 
The goals in this two-step process are to confirm the 
diagnosis of nephrolithiasis, then to identify the composition 
of the stones formed and the associated risk factors. 
Initial Evaluation 
Tests include dipstick urine assessment, serum chemistries, 
and a complete blood count (CBC). Urine dipstick assessment 
may be positive for blood, protein, or leukocyte esterase, 
indicating stones or fragments of stones present in the 
urinary tract. While nearly 10% of patients with stone 
disease exhibit gross hematuria, nearly 90% of patients have 
microscopic hematuria.  
Radiologic Evaluation  
Radiologic evaluation of stones is currently performed 
through plain x-rays, ultrasonography, and noncontrast 
spiral CT. When a patient presents with acute signs of 
nephrolithiasis, a plain film x-ray of the kidneys, ureters, and 
bladder (KUB) is acceptable as the first imaging study, as it is 
inexpensive and available in most areas.20 
Management and Treatment of Kidney Stones 
Pain relief. Provide analgesia, antiemetics, and intravenous 
hydration as needed at the evaluation. Nonsteroidal anti-
inflammatories (eg, ketorolac 15 to 30 mg intravenously) can 
provide effective analgesia, with opioids administered either 
concurrently for rapid relief or if the nonsteroidal anti-
inflammatory effect is insufficient. Use oral nonsteroidal 
anti-inflammatories with or without opioids for patients who 
are less symptomatic or for analgesia after discharge. 21, 22, 23 
If urgent intervention is not required, the treating physician 
needs to decide if the stone can be passed spontaneously. 
The likelihood of spontaneous passage decreases as the size 
of the stone increases and stones >5-6 mm are not likely to 
pass spontaneously. Patients who are having repeated stone 
attacks should be instructed to strain their urine and to 
submit the stone for composition analysis. Repeated imaging 
(plain abdominal radiography (KUB) for radiopaque stones 
and CT for radiolucent stones) is warranted to confirm stone 
passage. If follow-up imaging reveals no movement after a 
month, urologic intervention is generally warranted.6   
Significance of herbal therapy 
Medicinal plants have been known for millennia and are 
highly esteemed all over the world as a rich source of 
therapeutic agents for the prevention of various ailments. 
Today large number of population suffers from kidney stone, 
gall stone and urinary calculi. Stone disease has gained 
increasing significance due to changes in living conditions i.e. 
industrialization and malnutrition. Changes in prevalence 
and incidence, the occurrence of stone types and stone 
location, and the manner of stone removal are explained. 
Medicinal plants are used from centuries due to its safety, 
efficacy, cultural acceptability and lesser side effects as 
compared to synthetic drugs.14 
Standard pharmaceutical drugs used to prevent and cure 
urolithiasis are not effective in all cases, costly, quite 
common reoccurrences, risks of long term fertility, potential 
side effects and no guarantee.24, 25 Surgical treatment causes 
some problems like long term renal damage, hypertension 
and reoccurrence of stones. Extracorporeal shock wave 
lithotripsy is considered as a revolution in treating renal 
stones, but this treatment also causes some problems like 
long term renal damage, hypertension and reoccurrence of 
stones and so an approach is being extensively investigated 
to prevent or inhibit the stone reoccurrence, which resulted 
in treatment with hydrochlorothiazide, orthophosphate, 
alkali-citrates and magnesium to reduce the rate of stone 
reoccurrence. It is a well-known fact that glycosamino 
glycons and urinary proteins which are present in the 
matrices of the urinary stones are the strong inhibitors 
against CaOx crystal formation.26 References prove that 
litholytic herbs for treatment of renal stones are used since 
ancient periods before inventing modern treatments. 
Standard pharmaceutical drugs used to prevent and treat 
urolithiasis are not effective in all cases and also produce 
many adverse effects.24 Scientific studies are mostly focused 
on phytotherapy as it is proved to be vital in preventing 
reoccurance of stones. Herbal drugs are reported to be 
effective with no side effects. The drug for prevention of the 
disease or its reoccurrence is of great interest as no drug in 
clinical therapy is of satisfactory result.24  
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Table 4: List of plants used for the treatment of kidney stone and urinary tract troubles 27, 28, 29 
Sr. 
No 
Name of Plants 
Common 
name 
Family Part used Medicinal uses 
1 Abutilon indicum (L.) Sweet Jhumka Malvaceace 
Seed and 
leaf 
extracts 
Extract is given for urinary 
disorder 
2 Abutilon indicum (Linn.) Kanghi Malvaceae Leaves 
Juice taken twice daily for two 
weeks 
3 Ageratum conyzoides L. Gana gaaju Asteraceae Leaves Leaf extract given twice a day 
4 Amaranthus caudatus L. 
Love lies 
bleeding 
Amaranthaceae leaves Extract is taken in kidney stone 
5 
Aerva lanata (L.) Juss. ex 
Schult 
Pindikura Amaranthaceace leaves 
Plant extract with Cuminum 
cyminum fruits and sugar is given 
for 10-15 days to cure kidney 
stone. 
6 Amaranthus spinosus L. 
Jangali 
chauli 
Amaranthaceae Root 
Root paste use for reduces 
irritation in urinary duct 
7 Amaranthus viridis L. Piazi Liliaceae leaves Decoction of leaves 
8 Azadirachta indica A.Juss. Kaduneem Meliaceae 
Stem bark, 
Leaves 
Stem bark, Leaves 
9 Beta vulgaris L. 
Ullam 
gadda 
Amarantrhaceace Rhizome 
Daily two glass of rhizome juice for 
seven days to cure kidney stone 
10 Bauninia racemosa Lam Apta Caesalpiniaceae Stem bark Stem bark 
11 Bombex ceiba Linn. 
Silk cotton 
tree 
Bombacaceace 
Stem and 
bark 
Given for urinary problems 
12 
Butea monosperma (Lam.) 
Taub. 
Palas Fabaceae 
Leaves, 
seeds 
 Leaves juice or decoction 
is useful. 
 Seed powder in one 
teaspoon after meals is taken. 
13 Ceropegia bulbosa Roxb. Khadula Asclepidaceace Tubers 
Decoction of tubers orally to get rid 
of urinary bladder stone 
14 Chenopodium album Linn. Chilua Chenopodiaceae Leaves 
Cooked leaves as a vegetable given 
in urinary trouble 
15 Costus speciosus (Koen.) Sm. Mahalakri Costaceace Tubers 
Decoction of tubers orally for 
urinary complaints 
16 Cordia dichotoma (L.) Bhokar Boraginaceae 
Stem Bark, 
Fruits 
Stem Bark, Fruits 
17 Digera muricata (L.) Mart. 
Lesua, 
Latmahuria 
Amaranthaceae Leaves Once in a day 
18 Equisetum debile Roxb. 
Jod tod ki 
ghas 
Equistaceace All parts 
Whole plants juice along with 1 
gram Piper nigrum Linn. Twice a 
day for 7 days 
19 Gomphrena celosioides Mart. 
Gomphrena 
weed 
Amaranthaceae 
Whole 
plant 
Juice along with Piper nigrum Linn. 
And lemon juice twice a day for 10 
days 
20 
Hemidesmus indicus (L.) R. 
Br. 
Anantmul  Apocynaceae Root, leaf  
 Root powder is given 
daily morning, afternoon and 
evening. 
 Leaf decoction is used in 
morning and evening 
21 
Hygrophila auriculata (Sch.) 
Heine 
Talimkhana Acanthaceae Roots. Roots are given  
22 Kalanchoe pinnata (Lam.) Panphuti Craussulaceae Leaf  
Fresh leaves juice is given at any 
time. 
23 
Lagenaria siceraria 
(Molina) Standl. 
Dudhi bhopla Cucurbitaceae Fruits 
One cup of fruit juice is advised 
twice a day for seven days 
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24 Lagerstroemia parviflora  L. Lendya Lythracea Roots  
Roots are crushed and 1-2 gms are 
swallowed once a day, till gets rid 
of kidney stone. 
25 
Macratyloma uniflorum 
(Lam.) 
Kulthi, Kulith Fabaceae Fruits  
Boiled Fruits with cold water is 
given thrice a day. 
26 
Madhuka longifolia 
(J.Konig) 
Moh Sapotaceae Stem 
2 cm stem bark powder is soaked 
in 1 glass of water overnight. In 
morning, a pinch of white pepper 
powder and cumin seed powder is 
added and taken at empty stomach.  
This is taken once in a week. Total 
60 doses are required. 
27 
Meyna laxiflora Robyns, 
Bull. Jard 
Alu, Helu Rubiaceae Seed 
Five pinches of seed powder is 
mixed with water and given twice a 
day for 15 days. 
28 
Momordica diocia Roxb. ex. 
Willd 
Kartoli Cucurbitaceae 
Roots, 
Fruits. 
Roots, Fruits. 
29 Ocimum sanctum L. Tulas Lamiaceae Leaf  Leaves juice + Honey. 
30 Ocimum tenuiflorum L. Tulsi, Tulas Lamiaceae Leaf  
Entire plant should burn and ash 
mixed with water is given thrice a 
day 
31 
Pedalium murea Linn. 
(Pedaliaceace) 
Dakhigokhru Pedaliaceace Fruits 
Decoction of fruits used for 
continuance of urine and other 
complaints of urinary system 
32 Punica granatum  L. Anar, Dalimb Punciaceae Seed, fruits  Seed juice is given before breakfast 
33 
Raphanus sativus (L.) 
Domin 
Mula Brassicaceae 
Root, leaf, 
seed  
 Root juice is given after 
meals.  
 Leaf juice is given before 
breakfast.  
 Seed powder is useful 
before breakfast. 
34 Ricinus communis Arandi Euphorbiaceace Root 
Root decoction along with half 
gram sunthi + one gm of heeng + 
common salt given twice a day for 7 
days 
35 Solanum surattense Burn. 
Ber kaleli, 
neeli kateti 
Solanaceace 
Root 
powder 
Root powder + curd given daily for 
2 weeks 
36 
Tephrosia purpurea (L.) 
Pers. 
Sharapunkha, 
Unhali 
Fabaceae  
• Root powder or juice is 
useful if taken morning and 
evening. 
• Leaf decoction (one glass) 
before breakfast is given.  
• Entire plant boiled and 
juice is given after particular 
intervals. 
37 
Terminalia arjuna 
(Roxb.)Wight & Arn. 
Arjun, Sadada Combretaceae Bark  
Bark powder is given after 
breakfast, lunch and dinner. 
38 
Tinospora cordifolia 
(Wild.L) 
Gugul Menispermaceae Stem  
Crushed stem is given orally to 
expel the stone. 
39 Tribulus terrestris Linn. Gukhru Zygophyllaceae Leaves Used in treatment of kidney stone 
40 Tridex procumbens L. Molymehndi Asteraceace Leaves 
Leaf paste is used taken for kidney 
stone 
41 Tridex procumbens L. Kambarmodi Asteraceae Leaf  Leaf paste is given. 
42 
Tubiflora acaulis (L.F.) 
Kuntze 
Patta chatta Acanthaceace Leaf Leaf powder with water 
43 Zea mays L. Maka Poaceae  Paste given orally. 
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Herbal medicines act by multiple mechanisms like 
 Helping in spontaneous passage of calculi by increasing 
urine volume, pH and anticalcifying activity (Diuretic 
activity). 
 Balancing the Inhibitor and promoter of the 
crystallization in urine and affecting the crystal 
nucleation, aggregation and growth (Crystallization 
inhibition activity). 
 Relieving the binding mucin of calculi (Lithotroptic 
activity). 
 Improving renal function. 
 Regulation of oxalate metabolism. 
 Regulating the crystalloid-colloid imbalance and 
improving renal function, thus preventing recurrence 
of urinary calculi. 
 Improving renal tissue antioxidant status and cell 
membrane integrity and preventing recurrence 
(Antioxidant activity). 
 Exerting significant anti-infective action against the 
major causative organisms (Antimicrobial activity). 
 ACE and Phospholipase A2inhibition. 
 Relieving symptoms like pain, burning micturition and 
haematuria (Analgesic and anti-inflammatory 
activity).29 
Methods of evaluation of Anti-Urolithiasis Activity29, 30, 31  
Different screening model for urolithiasis and potential 
antiurolithiasis are divided in to in-vivo and in-vitro 
evaluation. This study will help scientist for selection of 
suitable model in search of antiurolithiasis compounds.  
IN VIVO ANIMAL MODEL 
 Ethylene glycol induced urolithiasis in rats. 
 Ethylene glycol and ammonium chloride induced 
urolithiasis in rats. 
 Sodium oxalate (NaOx) induced urolithiasis in rats. 
 Calculi-Producing diet induced urolithiasis  
 Glyoxylate induced acute lithiasis 
 Zinc disc induced urolithiasis in rats 
IN VITRO STUDIES ON UROLITHIASIS 
 Calcium oxalate crystal assay 
 Determination of effect on CaC2O4 crystallization 
 Nucleation Assay 
 Growth assay 
 Calcium phosphate assay 
 Lactate dehydrogenase leakage assay 
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